CAR T-cell Therapy

oncological-drugs-to-be-launch-in-2022
Most Promising Oncological Drugs Expected to Launch in 2022

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals...


car-t-cell-therapy-market-competitive-landscape-key-players
CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Therapies, Competitive...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative potential as a new type of cancer treatment that utilizes the immune system to fight the disease. It involves th...


Avrobios-Gene-Therapy-for-Cystinosis
Avrobio’s Gene Therapy for Cystinosis Treatment: A New Hope to Overcome the Existing Medical Unme...

Cystinosis is a genetic condition that causes the buildup of the amino acid "cystine" in the cells of the body is known as cystinosis. Due to the excessive accumulation of cystine in various cells...


chimeric-antigen-receptor-therapies-in-blood-cancers
A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in B...

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer i...


KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH therapy
KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Ata...

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the develop...


CAR-T cell therapy market for Non-Hodgkin lymphoma
CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. ...


Pharma News
CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of ...


CAR T cell therapy
66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy

In a groundbreaking clinical trial, a 66-year-old Ohio woman became the first patient to become cancer free through the CAR T Cell Therapy. In August this year, Denise Kennan had participated in th...


Gene Therapy
Is Gene Therapy the Next Cancer Treatment Revolution? 

Gene Therapy is now touted as a new revolution for cancer treatment. If the list of new cancer treatment methodologies is traversed, then the end seems to be farther and farther away. As a sequel t...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.